Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.
John R UssherDaniel J DruckerPublished in: Nature reviews. Cardiology (2023)
Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce body weight, glycaemia, blood pressure, postprandial lipaemia and inflammation - actions that could contribute to the reduction of cardiovascular events. Cardiovascular outcome trials (CVOTs) have demonstrated that GLP1R agonists reduce the rates of major adverse cardiovascular events in patients with T2DM. Separate phase III CVOTs of GLP1R agonists are currently being conducted in people living with heart failure with preserved ejection fraction and in those with obesity. Mechanistically, GLP1R is expressed at low levels in the heart and vasculature, raising the possibility that GLP1 might have both direct and indirect actions on the cardiovascular system. In this Review, we summarize the data from CVOTs of GLP1R agonists in patients with T2DM and describe the actions of GLP1R agonists on the heart and blood vessels. We also assess the potential mechanisms that contribute to the reduction in major adverse cardiovascular events in individuals treated with GLP1R agonists and highlight the emerging cardiovascular biology of novel GLP1-based multi-agonists currently in development. Understanding how GLP1R signalling protects the heart and blood vessels will optimize the therapeutic use and development of next-generation GLP1-based therapies with improved cardiovascular safety.
Keyphrases
- cardiovascular events
- coronary artery disease
- blood pressure
- cardiovascular disease
- type diabetes
- heart failure
- metabolic syndrome
- clinical trial
- atrial fibrillation
- oxidative stress
- emergency department
- big data
- cardiovascular risk factors
- skeletal muscle
- hypertensive patients
- open label
- physical activity
- deep learning
- body mass index